Autonomix Medical closed at $1.61 on Nov 4, down 3.01%, within 0.0% of its 52-week closing low. Volume of 81.2K shares was 1.54× its 20-day average (above normal).
Split-adjusted performance: -53.6% over one month, -80.1% over six months, -92.4% over one year.
Short interest was 59.0K shares at the Oct 15 settlement, up 119.9% from the prior report (3.4% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 110 companies (100 = best)
Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| AMIXAutonomix Medical | $1.61 | −3.01% | −80.1% | — | — | — | $3.2M | |
| CODXCo-Diagnostics | $0.3614 | −4.89% | — | +2.0% | −3782.4% | — | $3.2M | Compare |
| BJDXBluejay Diagnostics | $2.29 | +3.62% | −69.7% | — | — | — | $2.6M | Compare |
| AEMDAETHLON MEDICAL | $5.75 | −0.86% | −51.7% | — | — | — | $4.1M | Compare |
| ADGMAdagio Medical Holdings | $0.0862 | 0.00% | −91.1% | — | — | — | $2.4M | Compare |
| IVFINVO Fertility | $2.05 | +5.67% | −71.7% | +16.7% | 40.9% | — | $2.4M | Compare |
| XAIRBeyond Air | $2.33 | +0.43% | −79.4% | +0.5% | −448.8% | — | $2.3M | Compare |
| VVOSVivos Therapeutics | $0.1112 | +1.27% | −84.6% | +34.9% | −106.4% | — | $2.2M | Compare |
| NVNOenVVeno Medical | $7.00 | −2.43% | −30.5% | — | — | — | $4.9M | Compare |
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
